JP2023533417A5 - - Google Patents

Info

Publication number
JP2023533417A5
JP2023533417A5 JP2022567462A JP2022567462A JP2023533417A5 JP 2023533417 A5 JP2023533417 A5 JP 2023533417A5 JP 2022567462 A JP2022567462 A JP 2022567462A JP 2022567462 A JP2022567462 A JP 2022567462A JP 2023533417 A5 JP2023533417 A5 JP 2023533417A5
Authority
JP
Japan
Prior art keywords
sequence
seq
rna
cells
endonuclease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022567462A
Other languages
English (en)
Japanese (ja)
Other versions
JP7778087B2 (ja
JP2023533417A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/031136 external-priority patent/WO2021226363A1/en
Publication of JP2023533417A publication Critical patent/JP2023533417A/ja
Publication of JP2023533417A5 publication Critical patent/JP2023533417A5/ja
Priority to JP2025027249A priority Critical patent/JP2025090617A/ja
Application granted granted Critical
Publication of JP7778087B2 publication Critical patent/JP7778087B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022567462A 2020-05-08 2021-05-06 Ｒｕｖｃドメインを有する酵素 Active JP7778087B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025027249A JP2025090617A (ja) 2020-05-08 2025-02-21 Ｒｕｖｃドメインを有する酵素

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063022320P 2020-05-08 2020-05-08
US63/022,320 2020-05-08
US202063032464P 2020-05-29 2020-05-29
US63/032,464 2020-05-29
US202063116155P 2020-11-19 2020-11-19
US63/116,155 2020-11-19
US202163180570P 2021-04-27 2021-04-27
US63/180,570 2021-04-27
PCT/US2021/031136 WO2021226363A1 (en) 2020-05-08 2021-05-06 Enzymes with ruvc domains

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025027249A Division JP2025090617A (ja) 2020-05-08 2025-02-21 Ｒｕｖｃドメインを有する酵素

Publications (3)

Publication Number Publication Date
JP2023533417A JP2023533417A (ja) 2023-08-03
JP2023533417A5 true JP2023533417A5 (https=) 2024-03-14
JP7778087B2 JP7778087B2 (ja) 2025-12-01

Family

ID=78468763

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022567462A Active JP7778087B2 (ja) 2020-05-08 2021-05-06 Ｒｕｖｃドメインを有する酵素
JP2025027249A Pending JP2025090617A (ja) 2020-05-08 2025-02-21 Ｒｕｖｃドメインを有する酵素

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025027249A Pending JP2025090617A (ja) 2020-05-08 2025-02-21 Ｒｕｖｃドメインを有する酵素

Country Status (10)

Country Link
US (1) US20240209332A1 (https=)
EP (2) EP4467642A3 (https=)
JP (2) JP7778087B2 (https=)
KR (1) KR20230021657A (https=)
CN (1) CN116096892A (https=)
AU (1) AU2021267379A1 (https=)
CA (1) CA3177828A1 (https=)
GB (1) GB2612458B (https=)
MX (1) MX2022014067A (https=)
WO (1) WO2021226363A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021178933A2 (en) 2020-03-06 2021-09-10 Metagenomi Ip Technologies, Llc Class ii, type v crispr systems
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
US10913941B2 (en) * 2019-02-14 2021-02-09 Metagenomi Ip Technologies, Llc Enzymes with RuvC domains
WO2021202568A1 (en) 2020-03-31 2021-10-07 Metagenomi Ip Technologies, Llc Class ii, type ii crispr systems
CA3205865A1 (en) * 2021-01-22 2022-07-28 Brian C. Thomas Novel engineered and chimeric nucleases
AU2022335499A1 (en) 2021-08-27 2024-02-22 Metagenomi Therapeutics, Inc. Enzymes with ruvc domains
AU2022396533A1 (en) 2021-11-24 2024-05-02 Metagenomi Therapeutics, Inc. Endonuclease systems
CA3243006A1 (en) * 2021-12-21 2025-02-27 Alia Therapeutics Srl TYPE II CAS PROTEINS AND THEIR APPLICATIONS
WO2023137451A1 (en) * 2022-01-14 2023-07-20 Arbor Biotechnologies, Inc. Compositions comprising an rna guide targeting cd38 and uses thereof
WO2023194359A1 (en) * 2022-04-04 2023-10-12 Alia Therapeutics Srl Compositions and methods for treatment of usher syndrome type 2a
CA3267752A1 (en) * 2022-09-16 2024-03-21 Alia Therapeutics Srl ENQP TYPE II CAS PROTEINS AND THEIR APPLICATIONS

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015161276A2 (en) * 2014-04-18 2015-10-22 Editas Medicine, Inc. Crispr-cas-related methods, compositions and components for cancer immunotherapy
WO2017093969A1 (en) * 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
EP3423580A1 (en) * 2016-03-04 2019-01-09 Editas Medicine, Inc. Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
US20190136230A1 (en) * 2016-05-06 2019-05-09 Juno Therapeutics, Inc. Genetically engineered cells and methods of making the same
EP3500967A1 (en) * 2016-08-17 2019-06-26 The Broad Institute, Inc. Methods for identifying class 2 crispr-cas systems
WO2018073393A2 (en) * 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
EP3617311B1 (en) * 2017-03-30 2024-11-20 Kyoto University Method for inducing exon skipping by genome editing
MX2019013514A (es) * 2017-05-12 2020-01-20 Crispr Therapeutics Ag Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
US9982279B1 (en) * 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
EP3724326A1 (en) * 2017-12-11 2020-10-21 Editas Medicine, Inc. Cpf1-related methods and compositions for gene editing
WO2019165168A1 (en) * 2018-02-23 2019-08-29 Pioneer Hi-Bred International, Inc. Novel cas9 orthologs
CA3094468A1 (en) * 2018-04-05 2019-10-10 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
AU2019252925A1 (en) * 2018-04-13 2020-07-30 Sigma-Aldrich Co. Llc. Modification of immune-related genomic loci using paired CRISPR nickase ribonucleoproteins
CN113227374A (zh) * 2018-10-16 2021-08-06 因特利亚治疗公司 用于免疫疗法的组合物和方法
CA3241703C (en) * 2019-02-14 2026-02-24 Metagenomi Therapeutics, Inc. Enzymes with ruvc domains
JP2024515936A (ja) * 2021-03-19 2024-04-11 メタゲノミ，インク． Ｃａｓ酵素を用いたマルチプレックス編集

Similar Documents

Publication Publication Date Title
JP2023533417A5 (https=)
JP2023527354A5 (https=)
JP2021526853A5 (https=)
JP2022545385A5 (https=)
JP2025013884A5 (https=)
JP2024102277A5 (https=)
JP2007527244A5 (https=)
JP2024511163A5 (https=)
JP2024515936A5 (https=)
JP2024541811A5 (https=)
CN106282173B (zh) 克隆转基因生物中外源基因整合位点处侧翼序列的方法
JP2024517104A5 (https=)
Gardner et al. Functionalized lineage tracing for the study and manipulation of heterogeneous cell populations
JP2021522825A5 (https=)
CN105602972B (zh) 基于CRISPR-Cas9体外改造腺病毒载体的方法
JP2005511023A5 (https=)
CN112899276B (zh) 迷你启动子pHSP90AA1及其应用
JP2021507694A5 (https=)
Macias et al. Biology of Trypanosoma cruzi retrotransposons: from an enzymatic to a structural point of view
KR101231089B1 (ko) 기지의 서열에 인접한 미지의 ｄｎａ 서열을 증폭하는 방법
Pfleiderer et al. A novel vaccinia virus expression system allowing construction of recombinants without the need for selection markers, plasmids and bacterial hosts
CN113481194A (zh) 一种dna的合成方法
Clément et al. Cloning and sequencing of defective particles derived from the autonomous parvovirus minute virus of mice for the construction of vectors with minimal cis-acting sequences
CN110577969B (zh) CRISPR/Sa-SlugCas9基因编辑系统及其应用
Russell et al. cDNA cloning of the messenger RNAs of five genes of canine distemper virus